

Helsinki 16.6.2003

ESTUOIKEUSTODISTUS  
PRIORITY DOCUMENT

REC'D 30 JUN 2003

WIPO PCT



Hakija  
Applicant

Finnzymes Oy  
Espoo

Patentihakemus nro  
Patent application no

20020746

Tekemispäivä  
Filing date

18.04.2002

Kansainvälinen luokka  
International class

C12Q

Keksiinon nimitys  
Title of invention

"Method and materials for producing detection derivatives of  
polypeptides"  
(Menetelmä ja materiaalit polypeptidien deleetiojohdannaisten  
tuottamiseksi)

Täten todistetaan, että oheiset asiakirjat ovat tarkkoja jäljennöksiä  
Patentti- ja rekisterihallitukselle alkuaan annetuista selityksistä,  
patenttivaatimuksista, tiivistelmästä ja piirustuksista.

This is to certify that the annexed documents are true copies of the  
description, claims, abstract and drawings originally filed with the  
Finnish Patent Office.

*JL, Louise*  
Kristina Leukkasuo  
Tarkastaja

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Maksu 50 €  
Fee 50 EUR

Maksu perustuu kauppa- ja teollisuusministeriön antamaan asetukseen 1027/2001  
Patentti- ja rekisterihallituksen maksullisista suoritteista muutoksineen.

The fee is based on the Decree with amendments of the Ministry of Trade and Industry  
No. 1027/2001 concerning the chargeable services of the National Board of Patents and  
Registration of Finland.

Osoite: Arkadiankatu 6 A Puhelin: 09 6939 500 Telefax: 09 6939 5328  
P.O.Box 1160 Telephone: + 358 9 6939 500 Telefax: + 358 9 6939 5328  
FIN-00101 Helsinki, FINLAND

**BEST AVAILABLE COPY**

L1

## Method and materials for producing deletion derivatives of polypeptides

The present invention relates to genetic engineering and especially *in vitro* transposition. The invention describes a method and materials for producing deletion derivatives of polypeptide coding nucleic acids. In particular, the invention provides means for efficient generation of C-terminal deletions of polypeptides by the use of a modified transposon with translation stop codons in all three reading frames. The invention further provides a kit for producing said deletion derivatives.

### 10 BACKGROUND OF THE INVENTION

Thousands of different types of protein species constitute a major molecular component of cellular life. These molecules are composed of amino acid chains, the sequence of which is encoded by the genes in the organism's DNA. The protein function can be

15 diverse and specific functions have been evolved for different cellular demands. Native wild type protein molecules can obviously be studied for their function biochemically and genetically. The data thus obtained can be informative but very often such information is relatively limited. A better description of protein function can be gained through mutational analysis in which various types of mutations are introduced into the  
20 protein primary sequence and the mutated proteins are then analyzed for their function. With current recombinant DNA technology (Sambrook et al. 1989, Sambrook and Russell 2001), generation of mutations is relatively easy and therefore mutational analysis of proteins has become a standard in functional studies of proteins.

25 In principle, three different types of mutations can be introduced into a protein sequence (i) substitutions, (ii) insertions, and (iii) deletions. In a substitution mutation, a particular amino acid (or an amino acid stretch) in a protein is changed to another (or to another amino acid stretch of same length). In an insertion, an amino acid or a stretch of amino acids is added to the protein thus increasing the length of the amino acid chain.  
30 In a deletion mutation, an amino acid or a stretch of amino acids are eliminated from the protein sequence and thus the protein becomes smaller in size.

Various mutagenesis methods are currently available for generation of different types of mutations. These methods are typically straightforward to use. However, in most of the cases the wanted mutations are generated one by one and, therefore, their construction is time-consuming and labor-intensive. It would be desirable if a number of mutations 5 could be generated simultaneously. For certain types of insertion mutations this type of approach has been described (Hayes and Hallet 2000). However, an efficient method for simultaneous generation of substitution and deletion mutations is still lacking.

We utilised for the present invention a bacteriophage Mu-derived *in vitro* transposition 10 system that has recently been introduced (Haapa et al. 1999a) and shown to function efficiently in many types of molecular biology applications (Wei et al. 1997, Tairä et al. 1999, Haapa et al 1999 ab, Vilen et al. 2001). Mu transposition proceeds within the context of protein-DNA complexes that are called DNA transposition complexes or transpososomes (Mizuuchi 1991, Savilahti et al. 1995). These complexes are assembled 15 from a tetramer of MuA transposase protein and Mu-transposon-derived DNA-end-segments (i.e. transposon end sequences recognised by MuA) containing MuA binding sites. When the complexes are formed they can react in divalent metal ion-dependent manner with any target DNA and splice the Mu end segments into the target (Savilahti et al 1995). In the simplest case, the MuA transposase protein and a short 50 bp Mu 20 right-end (R-end) fragment are the only macromolecular components required for transpososome assembly (Savilahti et al. 1995, Savilahti and Mizuuchi 1996). Analogously, when two R-end sequences are located as inverted terminal repeats in a longer DNA molecule, transposition complexes form by synapsing the transposon ends. Target DNA in Mu DNA transposition *in vitro* can be linear, open circular, or 25 supercoiled (Haapa et al. 1999a).

Mu transposition complex, the machinery within which the chemical steps of transposition take place, is initially assembled from four molecules of MuA transposase protein that first bind specific binding sites in the transposon ends (Figs. 5A and 5B). 30 The 50 bp Mu right end DNA segment contains two of these binding sites (they are called R1 and R2 and each of them is 22 bp long, Savilahti et al. 1995). When two ends, each bound by two MuA monomers, meet, the transposition complex is formed through conformational changes, the nature of which are not fully understood because of a lack of atomic resolution structural data on Mu transpososomes. However, the assembly of

the minimal Mu transpososome is clearly dependent upon the correct binding of MuA transposase to Mu ends of the donor DNA. Thus, modifications in the conserved nucleotide sequence of transposon ends (e.g. R1 and R2 sequences in Mu R-end) should potentially have a negative effect on the efficiency of the transposition since every 5 altered nucleotide conceivably interferes with the MuA binding. It has been documented (Lee and Harshey 2001, Coros and Chaconas 2001) that the two last base pairs in the Mu transposon end can be modified without severe effect on transpososome function. However, no detailed analysis has been conducted for elucidation of the effects of modified R1 and R2 binding sites. In one example (Laurent et al. 2000) a *Not*I 10 restriction site was engineered close to the transposon end that changed one base pair in the R1 sequence. *In vivo* studies indicate that within the R1 and R2 sequences mutations generally have negative effects on transposition efficiency (Groenen et al. 1985, 1986). In addition, these effects are typically additive.

## 15 SUMMARY OF THE INVENTION

In this invention we describe a general methodology for making deletion derivatives of polypeptides using *in vitro* DNA transposition system. The method of the invention can be used to generate a number of deletion-derivatives of polypeptide coding nucleic 20 acids simultaneously and with ease.

We utilised modified transposons that allowed us to generate C-terminal deletion derivatives of polypeptides. The methodology should be applicable to any protein, the encoding nucleic acid sequence (e.g. a gene) of which is cloned in a plasmid or other 25 DNA vector.

In one aspect, the invention features a transposon nucleic acid comprising a genetically engineered translation stop signal in three reading frames at least partly within a transposon end binding sequence recognised by a transposase.

30 In various embodiments the transposon nucleic acid of the invention may contain a selectable marker and/or reporter gene. In one preferable embodiment the transposon end binding sequence of said transposon nucleic acid is Mu end sequence recognised by

MuA transposase. In one particular embodiment said Mu end sequence is Mu R-end sequence.

In a second aspect, the invention provides a method for producing a deletion derivative

5 of a polypeptide coding nucleic acid comprising the steps of:

(a) performing a transposition reaction in the presence of the transposon nucleic acid of the invention and a target nucleic acid containing a polypeptide coding nucleic acid of interest, (b) recovering a target nucleic acid having said transposon nucleic acid incorporated in said polypeptide coding nucleic acid.

10

In a preferred embodiment the method of the invention further comprises a step of (c) expressing said polypeptide coding nucleic acid having said transposon nucleic acid incorporated.

15

In a third aspect, the invention provides a kit for producing deletion derivatives of polypeptide coding nucleic acids. The kit comprises the transposon nucleic acid of the invention.

In a fourth aspect, the invention features use of the transposon nucleic acid of the

20

invention for producing deletion derivatives of polypeptide coding nucleic acids.

The term "transposon", as used herein, refers to a nucleic acid segment, which is recognised by a transposase or an integrase enzyme and which is essential component of a functional nucleic acid-protein complex capable of transposition (i.e. a

25

transpososome).

The term "transposase" used herein refers to an enzyme, which is an essential component of a functional nucleic acid-protein complex capable of transposition and which is mediating transposition. The term "transposase" also refers to integrases from

30

retrotransposons or of retroviral origin.

The expression "transposition reaction" used herein refers to a reaction wherein a transposon inserts into a target nucleic acid. Essential components in a transposition

reaction are a transposon and a transposase or an integrase enzyme or some other components needed to form a functional transposition complex. The method and materials of the present invention are exemplified by employing *in vitro* Mu transposition (Haapa et al. 1999ab and Savilahti et al. 1995). However, the Mu transposition method is not critical for this invention. Other transposition systems can be used as well. Examples of such systems are Tyl (Devine and Boeke, 1994, and International Patent Application WO 95/23875), Transposon Tn7 (Craig, 1996), Tn 10 and IS 10 (Kleckner et al. 1996), Mariner transposase (Lampe et al., 1996), Tcl (Vos et al., 1996, 10(6), 755-61), Tn5 (Park et al., 1992), P element (Kaufman and Rio, 1992) and Tn3 (Ichikawa and Ohtsubo, 1990), bacterial insertion sequences (Ohtsubo and Sekine, 1996), retroviruses (Varmus and Brown 1989) and retrotransposon of yeast (Boeke, 1989).

The term "transposon end sequence" used herein refers to the conserved nucleotide sequences at the distal ends of a transposon. The transposon end sequences are responsible for identifying the transposon for transposition.

The term "transposon end binding sequence" used herein refers to the conserved nucleotide sequences within the transposon end sequence whereto a transposase specifically binds when mediating transposition.

The term "target nucleic acid" used herein refers to a nucleic acid molecule containing a protein coding nucleic acid of interest.

The term "translation stop signal" used herein refers to the genetic code, which contains three codon triplets (UAA, UAG, UGA) for terminating the polypeptide chain production during protein synthesis in a ribosome. In a DNA strand the corresponding stop signal triplets are TAA, TAG and TGA.

The term "reading frame" used herein refers to any sequence of bases in DNA or RNA that codes for the synthesis of either a protein or a component polypeptide. The point of initiation of reading determines the frame, i.e. the way in which the bases will be grouped in triplets as required by the genetic code.

The term "genetic engineering" used herein refers to molecular manipulation involving the construction of artificial recombinant nucleic acid molecules.

5 The term "gene" used herein refers to genomic DNA or RNA that are translated into polypeptides.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10 **Figure 1.**

Cat-Mu transposons: Cat-Mu containing wild type Mu ends, Cat-Mu(*NotI*) containing Mu ends with engineered *NotI* restriction site, which design is described in Laurent et al. 2000, and Cat-Mu(Stop x 3) containing Mu ends with engineered translation stop signal in three reading frames (SEQ ID NO:2). Transposon end sequences (i.e. inverted terminal repeats) are drawn as rectangles.

15 **Figure 2.**

Transposon end sequences of Cat-Mu transposons: Cat-Mu transposon containing wild type Mu ends (SEQ ID NO:3), Cat-Mu(*NotI*) containing Mu ends with engineered *NotI* restriction site described in Laurent et al. 2000 (SEQ ID NO:4), and Cat-Mu(Stop x 3) containing Mu ends with engineered translation stop signal in three reading frames (SEQ ID NO:1). Asterisks (\*) show modified nucleotides in the Mu ends of Cat-Mu(*NotI*) and Cat-Mu(Stop x 3).

20 **Figure 3.**

25 Analysis of C-terminal deletion variants on DNA level. Plasmids bearing Cat-Mu(Stop x 3) transposon insertions (samples 1-24) were digested with BamHI, and they were analyzed on 1,8 % agarose gels. The length of the shortest fragment of each digest corresponds roughly to the length of the deletion variant protein gene (0- ~650 bp). M =  
30 DNA standards.

**Figure 4.**

Analysis of C-terminal deletion variants on protein level. The sizes of the deletion variant proteins, as predicted by sequencing analysis, are marked below each lane as kilodaltons. M= molecular weight standard, C<sup>+</sup>= positive control, C<sup>-</sup>= negative control.

5 Predicted deletion variant protein products are pointed out by arrows.

**Figures 5A and 5B**

5A, Mu transposition complex. 5B, the assembly of Mu transposition complex.

**10 Figure 6.**

Overall strategy for production of C-terminal deletion variants of genes encoding proteins.

**DETAILED DESCRIPTION OF THE INVENTION**

15

It has been published previously that protein engineering applications will benefit from Mu-based transposon strategies since it was established that any DNA sandwiched between Mu ends could be utilised as artificial transposons (Haapa et al. 1999a). In principle insertion mutations (e.g. by addition of epitope tags or protein domains) and deletion mutations (by addition of translation stop codons) were foreseen with this strategy. However, introduction of a translation stop codon between transposon ends would leave a number of encoded amino acid residues into the protein's C-terminus. Given that an effective Mu end is about 50 bp in length, minimally this strategy would leave approximately 18 extra amino acids attached in the protein C-terminus. Extra amino acids may interfere with the protein function, therefore it would be better to add the stop codons as close as possible to the transposon end. By modifying the nucleotides of the Mu R-end (total of 7 nucleotides were changed, 5 of said nucleotides reside in Mu R1 sequence), we managed to place three stop codons in three reading frames very close to the Mu R-end resulting in transposons that still surprisingly retained their ability to form transposition complexes that were competent for transposition chemistry, i.e. they facilitated the integration of the transposon *in vitro* into a target plasmid. In essence, all the possible C-terminal deletion variants can be generated.

We designed an artificial Cat-Mu(Stop)-transposon (SEQ ID NO:2) conferring resistance to chloramphenicol that in its ends contained modified base pairs providing three stop codons in three reading frames (figs. 1 and 2). The gene mediating resistance to chloramphenicol is used as a selectable marker. The term "selectable marker" refers to a gene that, when carried by a transposon, alters the ability of a cell harboring the transposon to grow or survive in a given growth environment relative to a similar cell lacking the selectable marker. The transposon nucleic acid of the invention preferably contains a positive selectable marker. A positive selectable marker, such as an antibiotic resistance, encodes a product that enables the host to grow and survive in the presence of an agent, which otherwise would inhibit the growth of the organism or kill it. The transposon nucleic acid of the invention may also contain a reporter gene, which can be any gene encoding a product whose expression is detectable and/or quantifiable by immunological, chemical, biochemical, biological or mechanical assays. A reporter gene product may, for example, have one of the following attributes: fluorescence (e.g., 15 green fluorescent protein), enzymatic activity (e.g., luciferase, *lacZ*/ $\beta$ -galactosidase), toxicity (e.g., ricin) or an ability to be specifically bound by a second molecule (e.g., biotin). The use of markers and reporter genes in prokaryotic and eukaryotic cells is well-known in the art. In a preferred embodiment the transposon nucleic acid of the invention may also contain genetically engineered restriction enzyme sites. For 20 example, the selectable marker gene within the transposon of the invention may influence the protein expression when a construct obtained by the method of the invention is inserted into a protein expression plasmid. It is therefore desirable to engineer a pair of unique restriction sites to flank the selectable marker gene. The marker can then be removed easily by the use of these sites and thus the final expression 25 construct would not contain the marker gene.

Hence, one embodiment of the invention provides a transposon nucleic acid comprising a genetically engineered translation stop signal in three reading frames at least partly within a transposon end binding sequence recognised by a transposase. Preferably, the 30 transposon nucleic acid of the invention comprises Mu transposon sequence. More preferably the transposon nucleic acid of the invention comprises Mu R-end sequence, e.g., the sequence of SEQ ID NO:1 or SEQ ID NO:5 (Mu-R end sequence not including 5' overhang, which thus can vary). In a transposon end sequence of the transposon

nucleic acid of the invention, translation stop signals of three reading frames are in 5'-to-3' direction, preferably in succession close to each other at a very end of a transposon, thus the three stop signals are as near as possible the flanking sequence after the transposon is incorporated into a target. Furthermore, the transposon end sequences, 5 which participate in the assembly of the transpososome discussed above, can be different from each other or they can be in different nucleic acid molecules. Preferably, both transposon end sequences participating in the transpososome have similar sequences (i.e. they are located as inverted terminal repeats). Although the transposon nucleic acid of the invention is exemplified here by transposons of Mu system only, a 10 person skilled in the art understands that teachings of this invention can be utilised in other transposon systems as well.

Another embodiment of the invention is a method for producing a deletion derivative of a polypeptide coding nucleic acid comprising the steps of:

15 (a) performing a transposition reaction in the presence of a target nucleic acid containing a polypeptide coding nucleic acid (e.g. a gene) of interest and in the presence of a transposon containing a genetically engineered translation stop signal sequence in three reading frames at least partly within a transposon end binding sequence recognised by a transposase, (b) recovering a target nucleic acid having said transposon 20 incorporated in said gene.

The transposition reaction (a) includes a transposon in a form of linear DNA molecule, transposase protein (e.g. MuA), and a target DNA as macromolecular components. Additionally, the transposition reaction contains suitable buffer components including 25 Mg<sup>2+</sup> ions critical for chemical catalysis. Buffer components such as glycerol and DMSO (or related chemicals or solvents) somewhat relax the requirements for transposition reaction (Savilahti et al. 1995). Transposon DNA, in principle, can be of any length given that it in each end contain a Mu end sequence. Typically, target DNA is in a form of circular plasmid. However, any double-stranded DNA molecule more than 30 25 bp is expected to serve as efficient target molecule (Savilahti et al. 1995, Haapa-Paananen et al. 2002). In transposition reaction the reaction components are incubated together; during the incubation transposition complexes first form and then react with target DNA splicing the transposon DNA into target DNA. This process yields

transposon integrations into target molecules. The stoichiometry of the reaction (excess target) generates target molecules each with a single integrated transposon. Most importantly, the integration site in each molecule can be different. Even though some sites in DNA are somewhat more preferred than others most of the phosphodiester bonds in DNA will be targeted (Haapa et al. 1999ab, Haapa-Paananen et al. 2002). In practice this means that the integration sites are selected essentially randomly.

In the Examples below deletion mutant libraries were planned to cover the gene of interest at least 10-fold, i.e. when the target gene was approximately 600 bp, the final pool should contain of a minimum of 6000 mutants. As a test protein we utilised 23 kDa yeast Msol protein (Aalto et al. 1997). Those skilled in the art can easily design different strategies for mutant library construction as such strategies are well-known in the art (see, e.g., Sambrook et al. 1989, Sambrook and Russell 2001).

A mutant library was produced as described in Example 2. Target nucleic acids with a transposon insertion were isolated by size-selective preparative agarose gel electrophoresis. A person skilled in the art may design different isolation methods as such methods are well-known in the art (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al, John Wiley & Sons: 1992). We screened individual deletion mutants by restriction analysis (fig. 3). This analysis demonstrates that in the library, there are variants of different sizes. A person skilled in the art can easily utilise different screening techniques. The screening step can be performed, e.g., by methods involving sequence analysis, nucleic acid hybridisation, primer extension or antibody binding. These methods are well-known in the art (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al, John Wiley & Sons: 1992).

We sequenced 23 C-terminal mutants. All the mutants carried the translation stop codons in three reading frames.

Finally, the protein expression analysis (fig. 4) demonstrated that different deletion variant proteins are produced. Probably due to lack of resolution in the utilised gel system, the supposedly expressed protein was not detectable when the deletion

derivative was 8 kDa or smaller. Alternatively, very small versions of the Ms01 protein may be proteolytically degraded inside the cells.

A further embodiment of the invention is a kit providing means for producing deletion derivatives of protein coding nuclear acid sequences. The kit comprises the transposon 5 nucleic acid of the invention. The kit can be packaged in a suitable container and preferably it contains instructions for using the kit.

The results of the invention show that, unexpectedly, it is possible to substantially modify conserved transposase binding sequences of the Mu transposon ends without 10 critically compromising the competence of the modified transposon to assemble transposition complexes and thereafter carry out transposition chemistry. Thus, the invention provides a straightforward solution to the problem of extra amino acids attached in the protein C-terminus of the deletion derivative which could be produced by a conventional transposition system, wherein the transposon used contains the 15 translation stop signals between the transposon ends.

The present invention is further described in the following examples, which are not intended to limit the scope of the invention.

20 EXAMPLES

EXAMPLE 1

*In vitro* transposition reaction

25 *In vitro* transposition reaction (25 µl) contained 720 ng cat-Mu(Stop) transposon as a donor, 500 ng plasmid pHis6-MSO1 as a target nucleic acid, 0.2 µg MuA, 25 mM Tris-HCl at pH 8.0, 100 µg/ml BSA, 15% (w/v) glycerol, 0.05% (w/v) Triton X-100, 126 mM NaCl and 10 mM MgCl<sub>2</sub>. The reaction was carried out at 30°C for 4h.

30 Further details and variables of *in vitro* Mu transposition are described in Haapa et al. 1999ab and Savilahti et al. 1995, incorporated herein by reference.

## EXAMPLE 2

5    **Generation of a pool of mutants with C-terminal deletions in *Mso1***

*In vitro* transposition reactions with Stop-Mu were performed essentially as described in Haapa *et al.* (1999a) with the exception that they contained 720 ng donor DNA (Stop-Mu x 3) and 0,88 µg MuA. Ten reactions were pooled, phenol and chlorophorm extracted, ethanol precipitated, and resuspended in 30 µl of water. Several 1 µl aliquots 10 were electrotransformed, each into 25 µl of DH5 $\alpha$  electrocompetent cells, as described (Haapa *et al.* 1999a). Transposon-containing plasmid clones were selected on LB plates containing Ap and Cm. A total of  $\sim 6 \times 10^5$  colonies were pooled and grown in selective LB-Ap-Cm medium at 37 °C for 3h after which plasmid DNA was prepared from the pool with Qiagen Plasmid Midi kit. This plasmid preparation was subjected to a *Xba*I- 15 *Hind*III double digestion and preparative agarose gel electrophoresis. The DNA fragment corresponding to transposon insertions into the *Mso1*-containing DNA fragment was isolated with QIAquick Gel Extraction Kit (Qiagen). This fragment was then ligated into the plasmid pHis6-MSO1 vector *Xba*I-*Hind*III backbone to generate a construct pool with transposon insertions located only within the *Mso1* gene. After 20 ligation, a pool of plasmids from  $\sim 5 \times 10^4$  colonies was prepared as described above. Approximately 110 000 colonies were pooled. Transposon-carrying *Mso1* fragments were cloned into clean vector backbone as described above and approximately 11 000 colonies were pooled in the final C-terminal deletion mutant library. At all stages, the transformants were selected with Ap and Cm.

25

## EXAMPLE 3

**Restriction and expression analysis of deletion mutants**

Mutant clones were analyzed for deletions by *Bam*HI digestion and DNA sequencing.

30    For protein expression analysis, single mutant plasmids were introduced into BL21(DE3) expression strain. Selective medium was inoculated with o/n culture of bacteria containing mutant plasmid and grown until OD<sub>600</sub> was 0,4-0,7. Protein expression was induced with 1 mM IPTG for 3 hours and samples were withdrawn for

SDS-PAGE analysis. Bacterial lysates were run on 15 % gels and stained with GelCode blue stain (Pierce) as recommended by the supplier.

## MATERIALS AND METHODS

5

### Bacteria, media, enzymes and reagents

Bacterial cultures were grown in Luria broth supplemented with appropriate antibiotics: ampicillin (Ap) at 100 µg/ml and chloramphenicol (Cm) at 10 µg/ml when required.

*Escherichia coli* strains were DH5 $\alpha$  (Life Technologies) and BL21(DE3) (Novagen).

10 MuA protein was purified in collaboration with Finnzymes (Espoo, Finland) essentially as described (Baker *et al.* 1993, Haapa *et al.* 1999a). Restriction enzymes and T4 DNA ligase were from New England Biolabs and Promega, Triton X-100 from Roche. Standard DNA techniques were performed as described (Sambrook and Russell 2001). Enzymes were used as recommended by suppliers. Sequencing was carried out at the

15 sequencing service unit of the Institute of Biotechnology, University of Helsinki.

### Plasmids and transposons

Plasmid pHis6-MSO1 contains the 633 bp Mso1 gene as an insert (Aalto *et al.* 1997).

The Cat-Mu(Stop) transposon (1254 bp) is a derivative of the Cat-Mu transposon (Haapa *et al.* 1999a), and they encode resistance to chloramphenicol (fig. 1 and 2). The Cat-Mu(Stop)-transposon ends were engineered to carry translation stop signals for both 5'-to-3' directions of dsDNA in all three reading frames. Sequencing was performed using the primer 5'-gct agt tat tgc tca gcg g-3' (SEQ ID NO:5).

## REFERENCES

**Aalto, M. K., Jäntti, J., Östling, J., Keränen, S. & Ronne, H.** 1997. Msolp: A yeast protein that functions in secretion and interacts physically and genetically with Sec1p. 5 Proc. Natl. Acad. Sci. USA **94**: 7331-7336.

**Berg, D. E., and M. M. Howe (ed.).** 1989. Mobile DNA. American Society for Microbiology, Washington D. C.

10 **Boeke J. D.** 1989. Transposable elements in *Saccharomyces cerevisiae* in Mobile DNA.

**Chaconas, G., B. D. Lavoie, and M. A. Watson.** 1996. DNA transposition: jumping gene machine, some assembly required. Curr. Biol. **6**:817-820.

15 **Coros, C. J., and G. Chaconas.** 2001. Effect of mutations in the Mu-host junction region on transpososome assembly. J. Mol. Biol. **310**:299-309.

**Craig N. L.** 1996. Transposon Tn7. Curr. Top. Microbiol. Immunol. **204**: 27-48.

20 **Craigie, R., and K. Mizuuchi.** 1987. Transposition of Mu DNA: joining of Mu to target DNA can be uncoupled from cleavage at the ends of Mu. Cell. **51**:493-501.

**Devine, S.E. and Boeke, J.D.**, Nucleic Acids Research, 1994, 22(18): 3765-3772.

25 **Groenen, M. A. M., and P. van den Putte.** 1986. Analysis of the ends of bacteriophage Mu using site-directed mutagenesis. J. Mol. Biol. **189**:597-602.

**Groenen, M. A. M., E. Timmers, and P. van den Putte.** 1985. DNA sequences at the ends of the genome of bacteriophage Mu essential for transposition. Proc. Natl. Acad. 30 Sci. USA. **82**:2087-2091.

Haapa, S., S. Taira, E. Heikkinen, and H. Savilahti. 1999a. An efficient and accurate integration of mini-Mu transposons *in vitro*: a general methodology for functional genetic analysis and molecular biology applications. *Nucleic Acids Res.* 27:2777-2784.

5 Haapa, S., S. Suomalainen, S. Eerikäinen, M. Airaksinen, L. Paulin, and H. Savilahti. 1999b. An efficient DNA sequencing strategy based on the bacteriophage Mu *in vitro* DNA transposition reaction. *Genome Res.* 9:308-315.

10 Haapa-Paananen, S., H. Rita, and H. Savilahti. 2002. DNA transposition of bacteriophage Mu. A quantitative analysis of target site selection *in vitro*. *J. Biol. Chem.* 277:2843-2851.

Hayes, F., and B. Hallet. 2000. Pentapeptide scanning mutagenesis: encouraging old proteins to execute unusual tricks. *Trends Microbiol.* 8:571-577.

15 Ichikawa H. and Ohtsubo E., *J. Biol. Chem.*, 1990, 265(31): 18829-32.

Kahman, R., and D. Kamp. 1979. Nucleotide sequences of the attachment sites of bacteriophage Mu. *Nature* 280:247-250.

20 Kaufman P. and Rio D.C. 1992. *Cell*, 69(1): 27-39.

Kleckner N., Chalmers R. M., Kwon D., Sakai J. and Bolland S. *Tn1O and IS10 Transposition and chromosome rearrangements: mechanism and regulation in vivo and in vitro*. *Curr. Top. Microbiol. Immunol.*, 1996, 204: 49-82.

25 Lampe D.J., Churchill M.E.A. and Robertson H.M., *EMBO J.*, 1996, 15(19): 5470-5479.

30 Laurent, L. C., M. N. Olsen, R. A. Crowley, H. Savilahti, and P. O. Brown. 2000. Functional characterization of the human immunodeficiency virus type 1 genome by genetic footprinting. *J. Virol.* 74:2760-2769.

Lee, I., and R. M. Harshey. 2001. Importance of the conserved CA dinucleotide at Mu termini. *J. Mol. Biol.* **314**:433-444.

Mizuuchi, K. 1992. Transpositional recombination: mechanistic insights from studies of Mu and other elements. *Annu. Rev. Biochem.* **61**:1011-1051.

Ohtsubo E. & Sekine Y. Bacterial insertion sequences. *Curr. Top. Microbiol. Immunol.*, 1996, **204**:1-26.

10 Park B.T., Jeong M.H. and Kim B.H., Taehan Misaengmul Hakhoechi, 1992, **27**(4): 381-9.

Sambrook, J., E. F. Fritch, and T. Maniatis. 1989. *Molecular Cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.

15 Sambrook, J. and D. W. Russell. 2001. *Molecular Cloning: a laboratory manual*, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.

Savilahti, H. and K. Mizuuchi. 1996. Mu transpositional recombination: donor DNA cleavage and strand transfer in trans by the Mu transposase. *Cell* **85**:271-280.

20 Savilahti, H., P. A. Rice, and K. Mizuuchi. 1995. The phage Mu transpososome core: DNA requirements for assembly and function. *EMBO J.* **14**:4893-4903.

25 Sherratt, D. J. (ed.). 1995. *Mobile genetic elements*. Oxford University Press, Oxford, U.K.

Surette, M. G., S. J. Buch, and G. Chaconas. 1987. Transpososomes: stable protein-DNA complexes involved in the in vitro transposition of bacteriophage Mu DNA. *Cell* **49**: 253-262.

**Taira, S., J. Tuimala, E. Roine, E. L. Nurmiaho-Lassila, H. Savilahti, and M. Romantschuk.** 1999. Mutational analysis of the *Pseudomonas syringae* pv. *tomato* *hrpA* gene encoding Hrp pilus subunit. *Mol. Microbiol.* **34**:737-744.

5 **Varmus H and Brown. P. A.** 1989. Retroviruses, in Mobile DNA. Berg D. E..and Howe M. eds. American society for microbiology, Washington D. C. pp.53-108.

10 **Vilen, H., S. Eerikäinen, J. Tornberg, M. Airaksinen, and H. Savilahti.** 2001. Construction of gene-targeting vectors: a rapid Mu in vitro DNA transposition-based strategy generating null, potentially hypomorphic, and conditional alleles. *Transgenic Res.* **10**:69-80.

**Vos J.C., Baere I. And Plasterk R.H.A.,** *Genes Dev.*, 1996,10(6): 755-61.

15 **Wei, S. Q., K. Mizuuchi, and R. Craigie.** 1997. A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration. *EMBO J.* **16**:7511-7520.

We claim:

1. A transposon nucleic acid comprising a genetically engineered translation stop signal in three reading frames at least partly within a transposon end binding sequence

5 recognised by a transposase.

2. The transposon nucleic acid according to claim 1, wherein said transposon contains a selectable marker and/or a reporter gene.

10 3. The transposon nucleic acid according to claim 1 or 2, wherein said transposon end binding sequence is Mu end binding sequence.

4. The transposon nucleic acid according to claim 3, wherein said Mu end binding sequence is Mu R-end binding sequence.

15 5. The transposon nucleic acid according to claim 4, wherein said transposon sequence is set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:5.

20 6. The transposon nucleic acid according to any one of the preceding claim, wherein said transposon further contains a genetically engineered restriction enzyme site.

7. Method of producing a deletion derivative of a polypeptide coding nucleic acid comprising the steps of:

(a) performing a transposition reaction in the presence of a target nucleic acid

25 containing a polypeptide coding nucleic acid of interest and in the presence of a transposon containing a genetically engineered translation stop signal sequence in three reading frames at least partly within a transposon end binding sequence recognised by a transposase, (b) recovering a target nucleic acid having said transposon incorporated in said protein coding nucleic acid.

30 8. The method according to claim 7 further comprising a step of (c) expressing said protein coding nucleic acid having said transposon incorporated.

9. The method according to claim 7 or 8, wherein said transposon comprises the transposon nucleic acid of any one of claims 2-6.

10. A kit for producing deletion derivatives of polypeptide coding nucleic acids  
5 comprising the transposon nucleic acid of any one of claims 1-6.

11. Use of the transposon nucleic acid of any one of claims 1-6 for producing deletion derivatives of polypeptide coding nucleic acids.

## (57) Abstract

The present invention describes an *in vitro* transposition-based methodology for generation of deletion derivatives of polypeptides. A modified artificial transposon was 5 designed that, close to the transposon ends, contained a modification with translation stop codons in three reading frames. Transposition complexes can be assembled using the modified transposon and essentially random integrations into the target plasmid, containing a polypeptide coding nucleic acid of interest, were recovered as a plasmid pool. Subsequent manipulation steps including restriction enzyme digestions and 10 ligation resulted in pools of mutant clones from which deletion derivatives of a polypeptide coding nucleic acid of interest and its respective deletion polypeptides could be produced.

## SEQUENCE LISTING

<110> Finnzymes Oy

<120> Method and materials for producing deletion derivatives  
of polypeptides

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Mu  
end sequence

<400> 1

gatctgattg attgaacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaac

54

<210> 2

<211> 1254

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Mu  
transposon

<400> 2

gatctgattg attgaacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaacggatcc 60  
tatcgtaat tattacctcc acggggagag cctgagcaaa ctggcctcag gcatttgaga 120  
agcacacggc cacactgctt ccggtagtca ataaaccggc aaaccagcaa tagacataag 180  
cggttattta acgaccctgc cctgaaccga cgaccgggtc gaatttgctt tcgaatttct 240  
gccatttcatc cgcttattat cacttattca ggcgttagcaa ccaggcggtt aagggcacca 300  
ataactgcct taaaaaaatt acgccccggcc ctggcactca tcgcagttact gttgttaattc 360  
attaaggcatt ctggcgacat ggaagccatc acaaaccggca tgatgaacctt gaatcgccag 420  
cggttattta accttgcgc cttgcgtata atatttggcc atggtaaaaaa cggggggcgaa 480  
gaagttgtcc atattggcca cgtttaatc aaaactgggtt aaactcaccgc agggattggc 540  
ttagacgaaa aacatattct caataaaaccc ttttagggaaa taggcccagggt tttcaccgtt 600  
acacgcacaca tcttgcgaat atatgtgttag aaactgcggg aaatcgctgtt ggtatttact 660  
ccagagcgat gaaaacgttt cagttgcgc atggaaaaacg gtgtacaacag ggtgaacact 720  
atccccatatc accagctcac cgtctttcat tgccatacgt aattccggat gagcattcat 780  
caggcgggca agaatgtgaa taaaggccgg ataaaacttg tgcttatttt tctttacgg 840  
ctttaaaaag gccgtaatat ccagctgaac ggtctgggtt taggtacatt gagcaactga 900  
ctgaaatgcc taaaaatgtt ctttacgtt ccattgggtt atatcaacgg tggtataatcc 960  
agtgatttt ttctccattt tagttccctt agctcctgaa aatctcgaca actcaaaaaaa 1020  
tacgcgggtt agtgatctt tttcattatg gtgaaagggtt gaaacctctt cgtgccgatc 1080  
aacgtctcat ttgcgcaaa agttggccca gggcttcccg gtatcaacag ggacaccagg 1140  
atttattttat tctgcgaaat gatctccgtt cacaggtatttattcgttgcgaaaaggatcc 1200  
gttttcgcatttcatcgttgcgaa acgctttcgc gttttcgtt caatcaatca gatc 1254

<210> 3  
<211> 54  
<212> DNA  
<213> Bacteriophage Mu

<400> 3  
gatctgaagc ggccgacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaac

54

<210> 4  
<211> 54  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified Mu  
end sequence

<400> 4  
gatctgcggc cgccgacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaac

54

<210> 5  
<211> 50  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified Mu  
end sequence without 5' overhang

<400> 5  
tgattgattg aacgaaaaac gcgaaagcgt ttcacgataa atgcgaaaac

50

<210> 6  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Sequencing  
primer

<400> 6  
gctagttatt gctcagcgg

19

Figure 1.





Figure 2.

Cat-Mu	R1	R2	
	GATCTGAAGCGGGGACGGAAAAACCGGAAAGCGTTTACGGATAAAATGCCAAAC ACTTCCGGCGTGTCTTTGGCTTTACGGTATTACGCTTTG		
Cat-Mu(NotI)	R1	R2	
	GATCTGCGGCCGACGAAAAACCGGAAAGCGTTTACGGATAAAATGCCAAAC ACGGCGGGCGGTGTCTTTGGCTTTACGGTATTACGCTTTG		
Cat-Mu(Stop x 3)	NotI	R1	R2
	GATCTGATTCGAAACCGAAAAACCGGAAAGCGTTTACGGATAAAATGCCAAAC ACTAACTTAACTTGGCTTTACGGTATTACGCTTTG		Stop x 3

Figure 3.



L5

4




Figure 4.

Figure 5A.

## Mu DNA transposition complex




Figure 5B.





Figure 6.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.